0. DOCID:26957 SCORE: 0.00252166348923786
DOCNO: 10399438
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: ultrastructure
QUALIFIER: pathology
QUALIFIER: ultrastructure
QUALIFIER: ultrastructure
QUALIFIER: ultrastructure
QUALIFIER: ultrastructure
AUTHOR: V I Tsygankov VI
AUTHOR: S I Shvets SI
AUTHOR: G L Mogileva GL
AUTHOR: V M Kindialov VM
AUTHOR: N P Mel'nikova NP
PUBTYPE: Journal Article
JOURNALTITLE: Klinicheskaia laboratornaia diagnostika.
COUNTRY: RUSSIA
TITLE: [The nuclear morphotypes of epithelial cells in breast diseases]
PUBDATE: 19990501
Staining of the nucleolar ribosome organizer with AgNO3 followed by computer analysis of images by discriminant analysis helped distinguish 6 morphological types in the cells of cytological preparations of mammary glands. Comparison of the morphometrical data and results of visual examination of cells showed that the first type included nonproliferating fibroadenoma and mastopathy, type 2 fibroadenoma and mastopathy with moderate proliferation of epithelium, type 3 fibroadenoma and mastopathy with precancer epithelial proliferation, and types 4-6 included malignant proliferating cells which are compatible with well, moderately, and poorly differentiated cancer.

1. DOCID:25662 SCORE: 0.00230632249274813
DOCNO: 11247482
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Intensive Care
QUALIFIER: surgery
QUALIFIER: methods
QUALIFIER: surgery
AUTHOR: G V Bondar' GV
AUTHOR: A V Borota AV
AUTHOR: S E Zolotukhin SE
AUTHOR: K N Oleĭnikov KN
AUTHOR: G G Psaras GG
AUTHOR: S D Vasil'ev SD
PUBTYPE: Journal Article
JOURNALTITLE: Klinichna khirurhiia / Ministerstvo okhorony zdorov'ia Ukraïny, Naukove tovarystvo khirurhiv Ukraïny.
COUNTRY: Ukraine
TITLE: [Intensive therapy and strategy of management of patients with rectal cancer after the colonic descending to the perineum]
PUBDATE: 20001201
Optimal tactic for management of the patients on various stages of treatment was elaborated together with surgical procedure, basing on the experience of 3500 operations conduction for cancer recti, mainly abdominal resection with colon descendant to perineum. Methods of preoperative preparation and anesthesiological support were stated as well as the tactics of postoperative management of patients.

2. DOCID:26617 SCORE: 0.00220589800459228
DOCNO: 9852402
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Gene Expression Regulation, Neoplastic
QUALIFIER: metabolism
QUALIFIER: metabolism
QUALIFIER: metabolism
AUTHOR: J Fujimoto J
AUTHOR: R Hirose R
AUTHOR: H Sakaguchi H
AUTHOR: T Tamaya T
AFFILIATION: Department of Obstetrics and Gynecology, Gifu University School of Medicine, Tsukasa-machi, Gifu City, Japan.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Oncology.
COUNTRY: SWITZERLAND
TITLE: Estrogen dependency in uterine endometrial cancers.
PUBDATE: 19981201
Estrogen dependency in uterine endometrial cancers involves complicated tumor biology. A transformed phenotype of uterine endometrial cancers is supported by estrogen-dependent oncogene (c-Ha-ras, c-fos and c-jun) expressions. The relative overexpression of estrogen receptor exon 5 splicing variant and the damaged expression of progesterone receptor A, which belong to a lack of estrogen dependency, are related to metastatic potential. The estrogen-related metastatic processes, detachment, invasion and angiogenesis in some uterine endometrial cancers can be inhibited by progestins.

3. DOCID:26929 SCORE: 0.00215105662617208
DOCNO: 11089384
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: secondary
QUALIFIER: drug therapy
QUALIFIER: therapeutic use
AUTHOR: J R Green JR
AFFILIATION: Novartis Pharma AG, Basel, Switzerland. jonathan.green@pharma.novartis.com
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Medizinische Klinik (Munich, Germany : 1983)
COUNTRY: GERMANY
TITLE: Anti-tumor potential of bisphosphonates.
PUBDATE: 20001001
In addition to inhibiting bone resorption, bisphosphonates also exert anti-tumor effects. The most potent compounds are the newer, nitrogen-containing bisphosphonates such as zoledronic acid. In vitro, bisphosphonates inhibit proliferation and induce apoptosis in human tumor cell lines, and interfere with cell adhesion, invasion and growth factor secretion. The combination of bisphosphonates with other anti-cancer drugs such as paclitaxel or tamoxifen markedly enhances these effects. In vivo, zoledronic acid has recently been shown to inhibit angiogenesis. Although bisphosphonates are very effective against bone metastases, their in vivo anti-tumor potential against visceral metastases remains to be explored.

4. DOCID:26258 SCORE: 0.0020698602578752
DOCNO: 9567249
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Bile
QUALIFIER: complications
QUALIFIER: complications
AUTHOR: A Hiraki A
AUTHOR: H Ueoka H
AUTHOR: M Tabata M
AUTHOR: K Kiura K
AUTHOR: A Bessho A
AUTHOR: H Yamane H
AUTHOR: N Nogami N
AUTHOR: M Harada M
AFFILIATION: Second Department of Medicine, Okayama University Medical School, Japan.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Lung cancer (Amsterdam, Netherlands)
COUNTRY: IRELAND
TITLE: Spontaneous biloma as a complication of small cell lung cancer.
PUBDATE: 19980201
Biloma is an extraductular collection of bile within a defined capsular space. Prior reports have documented an association between biloma and abdominal trauma, and between biloma and iatrogenic injury resulting from abdominal surgery, percutaneous catheter drainage, or transhepatic cholangiogram. To our knowledge, bilomas have not previously been associated with lung cancer. We report a case of spontaneous biloma that developed as a complication of small cell lung cancer.

5. DOCID:26251 SCORE: 0.0020698601601307
DOCNO: 9763866
AUTHOR: M Bontenbal M
AUTHOR: R de Wit R
AUTHOR: J G Klijn JG
AUTHOR: C Seynaeve C
AFFILIATION: Academisch Ziekenhuis Rotterdam-Daniel den Hoed Kliniek, afd. Interne Oncologie, Rotterdam.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nederlands tijdschrift voor geneeskunde.
COUNTRY: NETHERLANDS
TITLE: [Chemotherapy in metastasized breast carcinoma]
PUBDATE: 19980701
Metastatic breast cancer is still an incurable disease. Standard hormonal and chemotherapeutic treatment modalities yield at the best a survival advantage of 1 to 2 years. However, palliation is still the second, very important goal of treatment for metastatic disease. First-line chemotherapeutic treatment with an anthracycline-containing regimen induces a response in about half the patients. In second-line treatment docetaxel is an effective agent even in patients failing first-line therapy with an anthracycline-containing regimen. There is no effective standard third-line chemotherapy scheme.

6. DOCID:27314 SCORE: 0.0019336054580768
DOCNO: 9633320
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Indians, North American
QUALIFIER: organization & administration
QUALIFIER: ethnology
QUALIFIER: prevention & control
AUTHOR: H F Clarke HF
AUTHOR: R Joseph R
AUTHOR: M Deschamps M
AUTHOR: T G Hislop TG
AUTHOR: P R Band PR
AUTHOR: R Atleo R
AFFILIATION: Registered Nurses Association, British Columbia, Vancouver.
PUBTYPE: Journal Article
JOURNALTITLE: The Canadian nurse.
COUNTRY: CANADA
TITLE: Reducing cervical cancer among First Nations women.
PUBDATE: 19980301
First Nations women in British Columbia have a four to six times higher mortality rate from cancer of the cervix than do women in the general population. Their participation in the provincial Cervical Cytology Screening Program (CCSP) is less regular and less frequent than other women in B.C. Likewise, they have more difficulty in obtaining culturally suitable health care services from respectful and consistent professionals. These issues should be of critical concern to nurses, as nurses provide the majority of health services to First Nations people.

7. DOCID:27966 SCORE: 0.0019301410961885
DOCNO: 10442380
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
QUALIFIER: radiotherapy
AUTHOR: W Hoffmann W
AUTHOR: M Schiebe M
AUTHOR: J Dethling J
AUTHOR: C Martin C
AFFILIATION: Department of Radio-Oncology and Radiotherapy, Braunschweig Community Hospital, University of Hannover Medical School, Germany.
PUBTYPE: Clinical Trial
PUBTYPE: Clinical Trial, Phase I
PUBTYPE: Journal Article
PUBTYPE: Randomized Controlled Trial
JOURNALTITLE: Oncology (Williston Park, N.Y.)
COUNTRY: UNITED STATES
TITLE: UFT plus calcium folinate plus radiotherapy for recurrent rectal cancer.
PUBDATE: 19990701
Uracil and tegafur (in a molar ratio of 4:1 [UFT]) plus calcium folinate comprise the components of the oral agent, Orzel, which appears to have activity comparable to intravenously administered 5-fluorouracil. This article describes the design of an open-label, disease-oriented, phase I trial of UFT plus calcium folinate in combination with simultaneous pelvic radiation for recurrent rectal cancer. This trial is designed to determine the maximum tolerated dose and dose-limiting toxicity of this regimen.

8. DOCID:27949 SCORE: 0.00193014068563524
DOCNO: 9818227
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: pathology
QUALIFIER: pathology
QUALIFIER: pathology
QUALIFIER: pathology
AUTHOR: D L Page DL
AUTHOR: J F Simpson JF
AFFILIATION: Division of Anatomic Pathology, Vanderbilt University Medical Center, Medical Center North, Nashville, TN 37232, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current opinion in oncology.
COUNTRY: UNITED STATES
TITLE: Pathology of preinvasive and excellent prognosis breast cancer.
PUBDATE: 19981101
Our review of recent developments in breast cancer involving the evaluation of patients' tissues is aimed at indicators of increased cancer risk (i.e., the atypical hyperplasias) and lesions without metastatic capacity at time of detection, but those lesions with sufficient risk of attaining metastasis that treatment is mandated (i.e., the ductal carcinomas in situ). We also include invasive lesions with little capacity for metastatic behavior, and highlight the histologic criteria for their recognition, as well as their biologic and clinical characterization. Also discussed are advances in the understanding of diagnostic techniques, particularly core needle biopsy.

9. DOCID:27609 SCORE: 0.00192604700735708
DOCNO: 9800117
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Health Behavior
QUALIFIER: prevention & control
AUTHOR: F Baker F
AFFILIATION: Behavioral Research Center, American Cancer Society, Atlanta, GA 30329-4251, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current opinion in oncology.
COUNTRY: UNITED STATES
TITLE: Behavioral science applied to cancer screening.
PUBDATE: 19980901
Behavioral science has played an important role in gaining an understanding of behavior related to use of cancer screening; however, thus far this role has been limited mainly to breast and cervical cancer screening. Progress has been made recently in identifying barriers to cancer screening in underserved populations, the role of provider behavior in promoting screening adherence, and in beginning to understand behavioral issues related to genetic susceptibility. Research based on behavioral science theory is increasing, and there is need for more of this type of theory-based research focused on screening for other types of cancer in addition to breast and cervical screening.

10. DOCID:27630 SCORE: 0.00192604604498341
DOCNO: 9932085
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Taxoids
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
AUTHOR: C Couteau C
AUTHOR: J P Armand JP
AFFILIATION: Service d'oncologie médicale, hôpital Tenon, Paris, France.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Bulletin du cancer.
COUNTRY: FRANCE
TITLE: [Irinotecan-containing combinations in solid tumors, except colonic carcinomas]
PUBDATE: 19981201
Irinotecan is a new topoisomerase I inhibitor. It has demonstrated antitumor activity in solid tumors, independently of the histologic type, and in squamous cervical carcinoma. Its original mechanism of action offers the possibility to combine it with other drugs. In vitro and in vivo studies have demonstrated synergistic activity between irinotecan, cisplatin and etoposide. This article reviews the main published phases I and II studies with irinotecan. The limiting toxicity of combination schedules in neutropenia. The best results were obtained with the association cisplatin-irinotecan in lung cancer. For the combination etoposide-irinotecan the best schedule of administration remains to be determined.

11. DOCID:25639 SCORE: 0.00190141514284162
DOCNO: 11525566
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Bacterial Proteins
DESCRIPTOR: Papillomavirus, Human
QUALIFIER: immunology
QUALIFIER: immunology
QUALIFIER: therapy
QUALIFIER: immunology
QUALIFIER: therapy
QUALIFIER: immunology
QUALIFIER: immunology
AUTHOR: S Hunt S
AFFILIATION: dshunt@easynet.co.uk
PUBTYPE: Clinical Trial
PUBTYPE: Clinical Trial, Phase III
PUBTYPE: Journal Article
JOURNALTITLE: Current opinion in molecular therapeutics.
COUNTRY: England
TITLE: Technology evaluation: HspE7, StressGen Biotechnologies Corp.
PUBDATE: 20010801
StressGen is developing HspE7 (SGN-00101) as a potential therapy for human papillomavirus (HPV)-associated conditions. It is a recombinant fusion protein comprising the HPV E7 antigen and the heat shock protein, hsp65, from Mycobacterium bovis. By November 2000, it was in phase III trials for HPV-related anal dysplasia [405228]. Under an aggrement formed in November 1999, the US National Cancer Institute (NCI) is carrying out clinical trials with StressGen in diseases caused by HPV [347155].

12. DOCID:27520 SCORE: 0.00185891381459834
DOCNO: 9890695
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: economics
QUALIFIER: economics
QUALIFIER: methods
QUALIFIER: methods
AUTHOR: B E Hillner BE
AFFILIATION: Department of Internal Medicine and Massey Cancer Center, Virginia Commonwealth University Richmond, 23298, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Anti-cancer drugs.
COUNTRY: ENGLAND
TITLE: Review of cost-effectiveness assessments of chemotherapy in adjuvant and advanced breast cancer.
PUBDATE: 19981101
Economic assessments of treatment alternatives in breast cancer have been predominantly ones addressing the role and type of adjuvant therapy. These assessments have shown that the effectiveness of the intervention drives the cost-effectiveness results. Other key factors were the relative risk of recurrence, the time frame considered and only minimally the costs of the intervention. Assessments in advanced breast cancer are few in parallel with the limited number of phase III trials. Future assessments should address neoadjuvant therapy, high-dose adjuvant therapy and agents that alter disease associated complications agents such as biphosphonates.

13. DOCID:27514 SCORE: 0.00185891271883549
DOCNO: 9516075
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: pathology
QUALIFIER: physiology
AUTHOR: D Yee D
AFFILIATION: University of Texas Health Science Center at San Antonio, 78284-7884, USA. yeed@uthscsa.edu
PUBTYPE: Journal Article
JOURNALTITLE: Breast cancer research and treatment.
COUNTRY: NETHERLANDS
TITLE: The insulin-like growth factors and breast cancer--revisited.
PUBDATE: 19980201
In 1992, a special issue of Breast Cancer Research and Treatment was devoted to the insulin-like growth factors and breast cancer. In that issue, identification of the key components of the IGF system was reviewed and their potential role in breast cancer growth was described. In this issue, we revisit the IGF system with particular attention to data that further supports their role in the growth regulation of breast cancer. Several new facets of the IGF system are described, and several laboratories have more clearly defined how each individual component of the IGF system may influence breast cancer biology.

14. DOCID:27989 SCORE: 0.0018396073545297
DOCNO: 10482188
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Gene Therapy
QUALIFIER: therapy
AUTHOR: D Hrouda D
AUTHOR: M Perry M
AUTHOR: A G Dalgleish AG
AFFILIATION: Department of Oncology, St George's Hospital Medical School, London, UK.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Seminars in oncology.
COUNTRY: UNITED STATES
TITLE: Gene therapy for prostate cancer.
PUBDATE: 19990801
Prostate cancer is one of the leading causes of cancer deaths in the western hemisphere. A number of different gene therapy strategies are currently being evaluated. The ex vivo and many of the in vivo therapies involve stimulating a specific antitumor immune response. Autologous vaccines involving interleukin-2 (IL-2)- or granulocyte-macrophage colony-stimulating factor (GM-CSF)-transduced whole tumor cells showed great promise in animal models. Clinical trials of these and other vaccine strategies are underway. In vivo gene therapies involving the replacement of mutant tumor-suppressor genes, antisense strategies, and the insertion of suicide genes are also being evaluated in prostate cancer.